Active Clinical Trials
The list of clinical trials that are currently active at Sunway Cancer Centre. For those who are interested to participate in the current clinical trials, please contact us.
| No | Protocol ID | Project Full name | Therapeutic | PI | Status |
| 1 | D5162C00048 | An Open-label, Single-arm, Phase II, Multinational, Multicentre Study to Assess the Efficacy and Safety of 5 Years of Osimertinib in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (TARGET) | Oncology | Dr. Lim BK | Enrolling/On-going |
| 2 | 61186372NSC3005 | A Phase 3 Study of Adjuvant Amivantamab and Lazertinib Combination versus Single-Agent Osimertinib in Patients with Evidence of Minimal Residual Disease after Resection of EGFR-Mutated Non-Small Cell Lung Cancer |
Oncology | Dr. Jennifer Leong | Pending SIV |
| 3 | CPI 0610-04 | MANIFEST-2: A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI‑0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients | Haemato-oncology | Dr. Wong CL | On-going/No enrollment |
| 4 | KEYNOTE-B15 / EV-304) | A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304) | Oncology | Dr. Nik Aslan | Enrolling/On-going |
| 5 | ASC4START | Feasibility Survey for Asciminib in 1L CML A phase IIIb, multi-center, open-label, randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase |
Haemato-oncology | Dato Chang KM | Pending SIV |
| 6 | CJDQ443B12301 | A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer | Oncology | Dr Lim Boon Kow | Enrolling/On-going |
| 7 | NS-018-201 | A Phase 2b, Open-label, Multicenter, Randomized, Controlled, 2-Arm Study to Assess the Efficacy and Safety of Orally Administered NS-018 versus Best Available Therapy in Subjects with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/μL) | Haemato-oncology | Dr. Wong CL | Enrolling/On-going |
| 8 | CWCD118A12301 | AdvanTIG-306: A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of ociperlimab (WCD118/BGB-A1217) combined with tislelizumab (VDT482/BGB-A317) plus platinum-based doublet chemotherapy versus placebo combined with pembrolizumab plus platinum-based doublet chemotherapy as first-line therapy for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) | Oncology | Dr. Lim Boon Khaw | Site selected |
| 9 | 61186372NSC3004 | A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy | Oncology | Dr Kow KS | On-going/No enrollment |
